A Phase I Study of LOXO-338 in People with B-Cell Lymphomas

Share
Print

Full Title

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients with Advanced Hematologic Malignancies

Purpose

The purpose of this study is to find the highest dose of the investigational drug LOXO-338 that can be given safely in people with B-cell lymphoma that has come back or continued to grow despite initial treatment. The types of B-cell lymphoma being evaluated in this study are chronic lymphocytic leukemia/small lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, and Waldenstrom’s macroglobulemia.  

LOXO-338 blocks the activity of BCL-2, a protein that contributes to cancer cell growth. By blocking this protein, LOXO-338 may stop the growth of certain B-cell lymphomas. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have chronic lymphocytic leukemia/small lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, or Waldenstrom’s macroglobulemia. Patients’ cancers must have come back or continued to grow despite prior treatment.
  • Patients should recover from the serious side effects of previous therapies before receiving LOXO-338.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Lindsey Roeker at 646-608-4115.

Protocol

21-448

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators